HCC
VRTX icon

Hirtle Callaghan & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Hirtle Callaghan & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-112
Closed -$17K – 215
2017
Q3 		$17K Hold
112
– – ﹤0.01% 161
2017
Q2 		$14K Sell
112
-26
-19% -$3.13K ﹤0.01% 153
2017
Q1 		$16K Hold
138
– – ﹤0.01% 155
2016
Q4 		$10K Sell
138
-80
-37% -$6.51K ﹤0.01% 141
2016
Q3 		$19K Hold
218
– – ﹤0.01% 173
2016
Q2 		$19K Sell
218
-375
-63% -$32.4K ﹤0.01% 154
2016
Q1 		$46K Sell
593
-86
-13% -$7.78K 0.01% 135
2015
Q4 		$86K Hold
679
– – 0.02% 100
2015
Q3 		$70K Hold
679
– – 0.01% 144
2015
Q2 		$84K Buy
+679
New +$85.6K 0.03% 146
2013
Q4 		– Sell
-6
Closed – – 655
2013
Q3 		$0 Buy
+6
New +$477 ﹤0.01% 636

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return